huahaipharm(SH:600521) Xin Lang Cai Jing·2026-01-27 02:15Group 1 - Huahai Pharmaceutical's stock price dropped by 5.19% to 16.25 CNY per share, with a trading volume of 266 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 24.33 billion CNY [1] - The company, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty APIs [1] - The revenue composition of Huahai Pharmaceutical includes finished drug sales at 61.86%, API and intermediate sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Huahai Pharmaceutical, having reduced its holdings by 250,100 shares to 13.1675 million shares, representing 0.88% of the circulating shares [2] - The estimated floating loss for the Southern CSI 500 ETF today is approximately 11.72 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 144.69 billion CNY, achieving a year-to-date return of 13.99% and a one-year return of 53.16% [2]